News und Analysen
![Agilent Announces New Revolutionary Quadrupole Mass Spectrometers at ASMS 2022:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOXJFVnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--28a78b421c077dca5a77c9f5fe7431aacb2c753b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investchancen.png?locale=de)
Agilent Announces New Revolutionary Quadrupole Mass Spectrometers at ASMS 2022
Agilent Technologies Inc. (NYSE: A) today announced new LC/MS and GC/MS quadrupole mass spectrometers which will be on show at the 70th ASMS Conference on Mass Spectrometry and Allied Topics being
![Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancerhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer
Pfizer Inc. (NYSE:PFE) today announced overall survival (OS) results from the Phase 3 PALOMA-2 trial, which evaluated IBRANCE® (palbociclib) in combination with letrozole compared to placebo plus
![Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
![Dexcom to Showcase Expanded CGM Portfolio and Industry-leading Connectivity at 82nd Scientific Sessions of the American Diabetes Association: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzhqRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dc80e0ef4017de010dd6eedba979079258398fba/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Dexcom_Registered_no_bug.jpg?locale=de)
Dexcom to Showcase Expanded CGM Portfolio and Industry-leading Connectivity at 82nd Scientific Sessions of the American Diabetes Association
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase its expanded global portfolio of real-time continuous glucose
![Agilent to Participate in Goldman Sachs 43rd Annual Global Healthcare Conferencehttps://www.cyansecurity.com/:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3drTkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a50e5b152ef56a1fae7163b7955091be5e0c52c6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Download.png?locale=de)
Agilent to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
Agilent Technologies Inc. (NYSE: A) today announced the company will participate in the Goldman Sachs 43rd Annual Healthcare Conference on Wednesday, June 15, in Rancho Palos Verdes, California.
![Agilent Releases IVDR-Compliant Instruments, Kits, and Reagents for Use in the European UnionPexels:](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0c0TEE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--33228b75b0fcf622b6424d191dd5d6327e34b2a9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Gaming.jpg?locale=de)
Agilent Releases IVDR-Compliant Instruments, Kits, and Reagents for Use in the European Union
Agilent Technologies Inc. (NYSE: A) today announced that previously CE-IVD marked instruments, kits, and reagents were released as IVDR Class A on May 26, 2022, in compliance with the new EU IVDR
![Pfizer Provides Update on Ownership Interest in Haleonhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Provides Update on Ownership Interest in Haleon
Pfizer Inc. (NYSE: PFE) today provided an update on its ownership interest in Haleon plc (Haleon), the newly independent company which will hold the joint Consumer Healthcare business of GSK plc
![Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordabilityhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a live webcast at 3:45 p.m. EDT on Monday, June 6, 2022, with Angela Hwang, Group President, Pfizer
![Dexcom Issues Statement on Recent Market Speculation: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzhqRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dc80e0ef4017de010dd6eedba979079258398fba/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Dexcom_Registered_no_bug.jpg?locale=de)
Dexcom Issues Statement on Recent Market Speculation
DexCom, Inc. (NASDAQ:DXCM) today issued the following statement in response to recent media and market speculation:
“Like many companies, Dexcom’s Board and management team regularly review
![Agilent Announces Collaboration with APC on Real-Time Process Monitoring: https://www.flatex.at/fileadmin/dateien_flatex/images/logos/logo-claim_flatex-at_positiv_rgb.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG5oVVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b69713a1a725bfbdb6127b83617e316a5f0244d5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-claim_flatex-at_positiv_rgb.png?locale=de)
Agilent Announces Collaboration with APC on Real-Time Process Monitoring
Agilent Technologies Inc. (NYSE: A) today announced a collaboration agreement with APC Ltd., in which the companies commit to working towards combining their technologies to provide unique
![Quidel and Ortho Announce Expected Closing of Ortho Transaction](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Quidel and Ortho Announce Expected Closing of Ortho Transaction
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics
![Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of
![Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Bernstein 38th
![Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countrieshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries
Pfizer Inc. (NYSE: PFE) today launched ‘An Accord for a Healthier World.’ This groundbreaking initiative aims to provide all of Pfizer’s patented, high-quality medicines and vaccines available in
![Agilent Reports Second-Quarter Fiscal Year 2022 Financial Results: https://unsplash.com/photos/WUehAgqO5hE](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWJXUGc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--603baa72d12d3aa218f1a6ab4f509d5dce0e7989/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/markus-spiske-WUehAgqO5hE-unsplash.jpg?locale=de)
Agilent Reports Second-Quarter Fiscal Year 2022 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.61 billion for the second quarter ended April 30, 2022, an increase of 5% compared to the second quarter of 2021 and up 7% on a core
![Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitishttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
Pfizer Inc. (NYSE: PFE) today announced detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluating etrasimod, a once-daily, oral, selective
![Dexcom Announces Upcoming Conference Presentation: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzhqRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dc80e0ef4017de010dd6eedba979079258398fba/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Dexcom_Registered_no_bug.jpg?locale=de)
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that Brice Bobzien, Senior Vice President, Finance, will present an update on the company at the Piper Sandler Ophthalmology and Diabetes Symposium on
![Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dosehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the
![Agilent Announces Cash Dividend of 21 Cents per Share: https://unsplash.com/photos/MJX7-BAdkt0](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNU5VUmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--76ba01a2a910a483ec97f165a797124af2181edb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chris-liverani-MJX7-BAdkt0-unsplash.jpg?locale=de)
Agilent Announces Cash Dividend of 21 Cents per Share
Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 21 cents per share of common stock will be paid on July 27, 2022, to all shareholders of record as of the close of
![Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Agehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) expanded emergency use authorization (EUA) to include a booster dose after
![Quidel Announces Stockholder Approval of Ortho Acquisition and Business Combination](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Quidel Announces Stockholder Approval of Ortho Acquisition and Business Combination
Quidel Corporation (Nasdaq: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the previously
![Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Cervical Cancer: https://unsplash.com/photos/26h317_UMYM](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWQ3VlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--38e68a44ee750d34f6f5faef759cb6cd5851c091/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/ussama-azam-26h317_UMYM-unsplash.jpg?locale=de)
Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Cervical Cancer
Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, is now EU CE-IVD–marked for use in cervical cancer. PD-L1 IHC 22C3 pharmDx can be used as an aid in
![Humana Specialty Pharmacy Receives Prestigious National Patient Choice Award for Fifth Consecutive Year: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBaXNCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--3d3c39355769d1759c5221ae0bf511106538ecb5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Humana_logo.png?locale=de)
Humana Specialty Pharmacy Receives Prestigious National Patient Choice Award for Fifth Consecutive Year
Humana Specialty Pharmacy has won the MMIT Specialty Pharmacy Patient Choice Award in the PBM/Payer category for the fifth year in a row. The award recognizes best-in-class customer satisfaction
![Dexcom Announces Upcoming Conference Presentations: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzhqRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dc80e0ef4017de010dd6eedba979079258398fba/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Dexcom_Registered_no_bug.jpg?locale=de)
Dexcom Announces Upcoming Conference Presentations
DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor
![Pfizer to Acquire Biohaven Pharmaceuticalshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer to Acquire Biohaven Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire